Abstract

Review Article

Promising Future in the Detection of Oral Cancer by Using Advance Screening Technology

Mohamed Yasser Kharma*, Mohamed Sadek Alalwani and Manal Fouad Amer

Published: 30 December, 2016 | Volume 1 - Issue 1 | Pages: 022-33

Oral cancer has a tendency to be detected at late stage which is detrimental to the patients because of its high mortality and morbidity rates (survival rate 15-50% [1]). The incidence of oral cancer worldwide is approximately 3% of all malignancies, thus creating a significant worldwide health problem [2].

Read Full Article HTML DOI: 10.29328/journal.johcs.1001003 Cite this Article Read Full Article PDF

References

  1. Sidra Bano, David Maria Priscilla, Indira AP. Salivary Biomarkers for Oral Squamous Cell Carcinoma: An Overview. IJSS. 2015; 1: 39-45. Ref.: https://goo.gl/nrRsv2
  2. Johnson NW, Warnakulasuriya S, Gupta PC, Dimba E, Chindia M, et al. Global oral health inequalities inincidence and outcomes for oral cancer: causes and solutions. Adv Dent Res. 2011; 23: 237-246. Ref.: https://goo.gl/95jC9Y
  3. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012; 62: 10-29. Ref.: https://goo.gl/V5Wpln
  4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2009; 59: 225-249. Ref.: https://goo.gl/mzqCBJ
  5. Horowitz AM, Goodman HS, Yellowitz JA, Nourjah PA. The need for health promotion in oral cancer prevention and early detection. J Public Health Dent. 1996; 56: 319-330. Ref.: https://goo.gl/YrZPC2
  6. Ram S, Siar CH. Chemiluminescence as a diagnostic aid in the detection of oral cancer and potentially malignant epithelial lesions. Int J Oral and Maxillofac Surg. 2005; 34: 521-527. Ref.: https://goo.gl/sf6H1T
  7. Yamamoto N, Nomura T, Takeda E, Hanaue K, Yamauchi T, et al. The present conditions and the future prospects oral cancer examination running in our department. Shikwa Gakuho. 2005; 105: 96-102.
  8. Braakhuis BJ, Snijders PJ, Keune WJ, Meijer CJ, Ruijter-Schippers HJ, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. JNCI J Nat Cancer Inst. 2004; 96: 998-1006. Ref.: https://goo.gl/oN0cPJ
  9. Braakhuis BJ, Leemans CR, Brakenhoff RH. Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. Semin Cancer Biol. 2005; 15: 113-120. Ref.: https://goo.gl/s5YpYL
  10. Bigelow C, Patton L, Strauss R, Wilder R. North Carolina dental hygienist’s view on oral cancer control. Journal of Dent Hyg. 2007; 81. Ref.: https://goo.gl/P8kZeL
  11. Patton LL, Epstein JB, Kerr AR. Adjunctive techniques for oral cancer examination and lesion diagnosis: A systemic review of the literature. J Am Dent Assoc. 2008; 139: 896-905. Ref.: https://goo.gl/dZnwpH
  12. Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005. Bethesda (MD): National Cancer Institute. 2008.
  13. Lippman SM, Hong WK. Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys. 1989; 17: 691-694. Ref.: https://goo.gl/rWKOtd
  14. Rennemo E, Zatterstrom U, Boysen M. Impact of second primary tumors on survival in head and neck cancer: an analysis of 2,063 cases. Laryngoscope. 2008; 118: 1350-1356. Ref.: https://goo.gl/0j1i41
  15. Whited JD, Grichnik JM. The rational clinical examination. Does this patient have a mole or a melanoma? JAMA. 1998; 279: 696-701. Ref.: https://goo.gl/Gqvkxs
  16. Rampen FH, Casparie-van Velsen JI, van Huystee BE, Kiemeney LA, Schouten LJ. False-negative findings in skin cancer and melanoma screening. J Am Acad Dermatol. 1995; 33: 59-63. Ref.: https://goo.gl/eeH03o
  17. Thomson PJ. Field change and oral cancer: new evidence for widespread carcinogenesis? Int J Oral Maxillofac Surg. 2002; 31: 262-266. Ref.: https://goo.gl/KgN2WY
  18. McGee S, Mardirossian V, Elackattu A, Mirkovic J, Pistey R, et al. Anatomy-based algorithms for detecting oral cancer using reflectance and fluorescence Ann Otol Rhinol Laryngol. 2009; 118: 17-26. Ref.: https://goo.gl/IlGrss
  19. Schwarz RA, Gao W, Redden Weber C, Kurachi C, Lee JJ, et al. Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy. Cancer. 2009; 115: 1669-1679. Ref.: https://goo.gl/ZkceY2
  20. Hu S, Arellano M, Boontheung P, Wang J, Zhou H, et al. Salivary proteomics oral cancer biomarker discovery. Clin Cancer Res. 2008; 14: 6246-6252. Ref.: https://goo.gl/e79bIr
  21. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009; 15: 5473-5477.Ref.: https://goo.gl/AUtY1S
  22. Weigum SE, Floriano PN, Redding SW, Yeh CK, Westbrook SD, et al. Nano-bio-chip sensor platform for examination of oral exfoliative cytology. Cancer Prev Res. 2010; 3: 518-528. Ref.: https://goo.gl/C2JwpJ
  23. Carvalho AL, Jeronimo C, Kim MM, Henrique R, Zhang Z, et al. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res. 2008; 14: 97-107. Ref.: https://goo.gl/ljzLz0
  24. Kaugars GE, Silverman S Jr, Ray AK, Page DG, Abbey LM, et al. The use of exfoliative cytology for the early diagnosis of oral cancers: is there a role for it in education and private practice? J Cancer Educ. 1998; 13: 85-89. Ref.: https://goo.gl/KlW7Q7
  25. Ogden GR, Cowpe JG, Green MW. Detection of field change in oral cancer using oral exfoliative cytologic study. Cancer. 1991; 68: 1611-1615. Ref.: https://goo.gl/j5bLZG
  26. Spafford MF, Koch WM, Reed AL, Califano JA, Xu LH, et al. Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis. Clin Cancer Res.2001; 7: 607-612. Ref.: https://goo.gl/l5Sv33
  27. Boyle JO, Mao L, Brennan JA, Koch WM, Eisele DW, et al. Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. Am J Surg.1994; 168: 429-432. Ref.: https://goo.gl/CMPyv5
  28. Williams HK. Molecular pathogenesis of oral squamous carcinoma. Mol Pathol. 2000; 53: 165-172. Ref.: https://goo.gl/EJebgx
  29. Remmerbach TW, Weidenbach H, Müller C, Hemprich A, Pomjanski N, et al. Diagnostic value of nucleolar organizer regions (AgNORs) in brush biopsies of suspicious lesions of the oral cavity. Anal Cell Pathol. 2003; 25: 139-146. Ref.: https://goo.gl/dVQUu2
  30. Ogden GR, Chisholm DM, Adi M, Lane EB. Cytokeratin expression in oral cancer and its relationship to tumour differentiation. J Oral Pathol Me. 1993; 22: 82-86. Ref.: https://goo.gl/tA7AUK
  31. Ogden GR, McQueen S, Chisholm DM, Lane EB. Keratin profiles of normal and malignant oral mucosa using exfoliative cytology. J Clin Pathol.1993; 46: 352-356. Ref.: https://goo.gl/UqkhzX
  32. Ogden GR, Cowpe JG, Chisholm DM, Lane EB. DNA and keratin analysis of oral exfoliative cytology in the detection of oral cancer. Eur J Cancer B Oral Oncol.1994; 30: 405-408. Ref.: https://goo.gl/iEpBfK
  33. Joseph BK. Oral cancer: prevention and detection. Med Princ Pract. 2002; 11: 32-35. Ref.: https://goo.gl/Q2xUcH
  34. Kosicki DM, Riva C, Pajarola GF, Burkhardt A, Gratz KW. OralCDx brush biopsy-a tool for early diagnosis of oral squamous cell carcinoma. Schweiz Monatsschr Zahnmed. 2007; 117: 222-227. Ref.: https://goo.gl/mpPc7Z
  35. Rick GM. Oral brush biopsy: the problem of false positives. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003; 96: 252. Ref.: https://goo.gl/UZrHP6
  36. Cowpe JG, Longmore RB, Green MW. Quantitative exfoliative cytology of abnormal oral mucosal smears. J R Soc Med. 1988; 81: 509-513. Ref.: https://goo.gl/vX5oQO
  37. Ramaesh T, Mendis BR, Ratnatunga N, Thattil RO. Cytomorphotometric analysis of squames obtained from normal oral mucosa and lesions of oral leukoplakia and squamous cell carcinoma. J Oral Pathol Med. 1998; 27: 83-86. Ref.: https://goo.gl/go39zo
  38. Zhang L, Williams M, Poh CF, Laronde D, Epstein JB, et al. Toluidine blue staining identifi es high-risk primary oral premalignant lesions with poor outcome. Cancer Res. 2005; 65: 8017-8021. Ref.: https://goo.gl/mH3b3h
  39. Gandolfo S, Pentenero M, Broccoletti R, Pagano M, Carrozzo M, et al. Toluidine blue uptake in potentially malignant oral lesions in vivo: clinical and histological assessment. Oral Oncol. 2006; 42: 89-95. Ref.: https://goo.gl/wFUOGy
  40. Pabiszczak M, Wierzbicka M, Wasniewska E, Szyfter W. Toluidine blue in monitoring of recurrences and second primary tumors in patients treated for oral cavity and pharynx cancer. Otolaryngol Pol. 2006; 60: 691-695. Ref.: https://goo.gl/QI70qr
  41. Epstein JB, Gorsky M, Lonky S, Silverman S Jr, Epstein JD, et al. The efficacy of oral lumenoscopy (ViziLite) in visualizing oral mucosal lesions. Spec Care Dentist. 2006; 26: 171-174. Ref.: https://goo.gl/f5AsqX
  42. Wong DT. Salivary diagnostics for oral cancer. J Calif Dent Assoc. 2006; 34: 303-308. Ref.: https://goo.gl/j5h32N
  43. Wong DT. Salivary diagnostics powered by nanotechnologies, proteomics and genomics. J Am Dent Assoc. 2006; 137: 313-321. Ref.: https://goo.gl/aG5zql
  44. Castagnola M, Picciotti PM, Messana I, Fanali C, Fiorita Am, et al. Potential applications of human saliva as diagnostic fluid. Acta Otorhinolaryngol Ital. 2011; 31: 347-357. Ref.: https://goo.gl/e8EHmy
  45. Shpitzer T, Bahar G, Feinmesser R, Nagler RM. A comprehensive salivary analysis for oral cancer diagnosis. J Cancer Res Clin Oncol. 2007; 133: 613-617. Ref.: https://goo.gl/ouWlZY
  46. Mizukawa N, Sugiyama K, Fukunaga J, Ueno T, Mishima K, et al. Defensin-1, a peptide detected in the saliva of oral squamous cell carcinoma patients. Anticancer Res. 1998; 18: 4645-4649. Ref.: https://goo.gl/TJTRn7
  47. Chen YC, Li TY, Tsai MF. Analysis of the saliva from patients with oral cancer by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom. 2002; 16: 364-369. Ref.: https://goo.gl/Om9gsI
  48. Pickering V, Jordan RC, Schmidt BL. Elevated salivary endothelin levels in oral cancer patients-a pilot study. Oral Oncol. 2007; 43: 37-41. Ref.: https://goo.gl/Zoqclk
  49. St John MA, Li Y, Zhou X, Denny P, Ho CM, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004; 130: 929-935. Ref.: https://goo.gl/7eWpHq
  50. Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F. NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev. 2005; 29: 42-45. Ref.: https://goo.gl/kxWFGo
  51. Nagler R, Bahar G, Shpitzer T, Feinmesser R. Concomitant analysis of salivary tumor markers-a new diagnostic tool for oral cancer. Clin Cancer Res. 2006; 12: 3979-3984. Ref.: https://goo.gl/zh6pu
  52. Vucicevic Boras V, Cikes N, Lukac J, Virag M, Cekic-Arambasin A. Salivary and serum interleukin 6 and basic fibroblast growth factor levels in patients with oral squamous cell carcinoma. Minerva Stomatol. 2005; 54: 569-573. Ref.: https://goo.gl/Wyug6c
  53. Hu S, Arellano M, Boontheung P, Wang J, Zhou H. Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res. 2008; 14: 6246-6252. Ref.: https://goo.gl/Qv3QHp
  54. Katakura A, Kamiyama I, Takano N, Shibahara T, Muramatsu T. Comparison of salivary cytokine levels in oral cancer patients and healthy subjects. Bull Tokyo Dent Coll. 2007; 48: 199-203. Ref.: https://goo.gl/6I85ZE
  55. Jou YJ, Lin CD, Lai CH, Chen CH, Kao JY. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. Anal Chim Acta. 2010; 681: 41-48. Ref.: https://goo.gl/Ms4P1K
  56. Franzmann EJ, Reategui EP, Pedroso F, Pernas FG, Karakullukcu BM, et al. Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1348-1355. Ref.: https://goo.gl/i5u9Zm
  57. Shpitzer T, Hamzany Y, Bahar G, Feinmesser R, Savulescu D. Salivary analysis of oral cancer biomarkers. Br J Cancer. 2009; 101: 1194-1198. Ref.: https://goo.gl/P2Vuxv
  58. He H, Chen G, Zhou L, Liu Y. A joint detection of CEA and CA-50 levels in saliva and serum of patients with tumors in oral region and salivary gland. J Cancer Res Clin Oncol. 2009; 135: 1315-1321. Ref.: https://goo.gl/uPzchr
  59. Shpitzer T, Bahar G, Feinmesser R, Nagler RM. A comprehensive salivary analysis for oral cancer diagnosis. J Cancer Res Clin Oncol. 2007; 133: 613-617. Ref.: https://goo.gl/okwi1w
  60. Jessie K, Jayapalan JJ, Ong KC, Abdul Rahim ZH, Zain RM, et al. Aberrant proteins in the saliva of patients with oral squamous cell carcinoma. Electrophoresis. 2013; 34: 2495-2502. Ref.: https://goo.gl/rX73Kz
  61. Jou YJ, Lin CD, Lai CH, Tang CH, Huang SH, et al. Salivary zinc finger protein 510 peptide as a novel biomarker for detection of oral squamous cell carcinoma in early stages. Clin Chim Acta. 2011; 412: 1357-1365. Ref.: https://goo.gl/uYCchU
  62. El-Naggar AK, Mao L, Staerkel G, Coombes MM, Tucker SL, et al. Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening. J Mol Diagn. 2001; 3: 164-170. Ref.: https://goo.gl/qliZRP
  63. Carvalho AL, Henrique R, Jeronimo C, Nayak CS, Reddy AN, et al. Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance. Clin Cancer Res. 2011; 17: 4782-4789. Ref.: https://goo.gl/xP3tO1
  64. Li Y, St John MA, Zhou X, Kim Y, Sinha U, et al. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res. 2004; 10: 8442-8450. Ref.: https://goo.gl/CmhfkF
  65. Bernabe DG, Tamae AC, Miyahara GI, Sundefeld ML, Oliveira SP, et al. Increased plasma and salivary cortisol levels in patients with oral cancer and their association with clinical stage. J Clin Pathol. 2012; 65: 934-939. Ref.: https://goo.gl/yprN95
  66. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010; 6: 78-95. Ref.: https://goo.gl/fXhSOF
  67. Vajaria BN, Patel KR, Begum R, Shah FD, Patel JB, et al. Evaluation of serum and salivary total sialic acid and alpha-l-fucosidase in patients with oral precancerous conditions and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013; 115: 764-771. Ref.: https://goo.gl/z8hVsh
  68. Wei J, Xie G, Zhou Z, Shi P, Qiu Y, et al. Salivary metabolite signatures of oral cancer and leukoplakia. Int J Cancer. 2011; 129: 2207-2217. Ref.: https://goo.gl/HaBuuD
  69. Banks RE, Dunn MJ, Hochstrasser DF, Sanchez JC, Blackstock W, et al. Proteomics: new perspectives, new biomedical opportunities. Lancet. 2000; 18: 1749-1756. Ref.: https://goo.gl/zFMrVy
  70. Li Y, St John MAR, Zhou X, Kim Y, Sinha U, et al. Salivary trans-criptome diagnostics for oral cancer detection. Clin Cancer Res. 2004; 10: 8442-8450. Ref.: https://goo.gl/pV0Eqp
  71. Li Y, Zhou X, StJohn MAR, Wong DT. RNA Profiling of cell-free saliva usingmicroarray technology. J Dent Res. 2004; 83: 199-203. Ref.: https://goo.gl/1V6QNr
  72. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. Oral Oncol. 2006; 42: 461-474. Ref.: https://goo.gl/kQgg98
  73. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Oral premalignant lesions: is a biopsy reliable? J Oral Pathol Med. 2007; 36: 262-266. Ref.: https://goo.gl/m3lQCE
  74. Scully C, Sudbø J, Speight PM. Progress in determining the malignant potential of oral lesions. J Oral Pathol Med. 2003; 32: 251-256. Ref.: https://goo.gl/AqRBzc
  75. Rosin MP, Lam WL, Poh C, Le ND, Li RJ, et al. 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res. 2002; 62: 6447-6450. Ref.: https://goo.gl/tFGHd2
  76. Tabor MP, Brakenhoff RH, van Houten VMM, Kummer JA, Snel MHJ, et al. Persistence of genetically altered fields in head and neck cancer patients: Biological and clinical implications. Clin Cancer Res. 2001; 7: 1523-1532. Ref.: https://goo.gl/gsXiAT
  77. Braakhuis BJM, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Research. 2003; 63: 1727-1730. Ref.: https://goo.gl/W15g1R
  78. Partridge M, Pateromichelakis S, Phillips E, Emilion GG, Ahern RP, et al. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res. 2000; 60: 3893-3898. Ref.: https://goo.gl/nma83F
  79. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat. Med. 1996; 2: 682-685. Ref.: https://goo.gl/S6TPUV
  80. Guo Z, Yamaguchi K, Sanchez-Cespedes M, Westra WH, Koch WM. Allelic losses in OraTest-directed biopsies of patients with prior upper aerodigestive tract malignancy. Clin Cancer Res. 2001; 7: 1963-1968. Ref.: https://goo.gl/fF1dRF
  81. Nawroz H, van der Riet P, Hruban RH, Koch W, Ruppert JM. Allelotype of head and neck squamous cell carcinoma. Cancer Res. 1994; 54: 1152-1155. Ref.: https://goo.gl/DxNeyV
  82. Zhang L, Williams M, Poh CF, Laronde D, Epstein JB, et al. Toluidine blue staining identifi es high-risk primary oral premalignant lesions with poor outcome. Cancer Res. 2005; 65: 8017-8021. Ref.: https://goo.gl/ffvKch
  83. Epstein JB, Zhang L, Poh C, Nakamura H, Berean K, et al. Increased allelic loss in toluidine blue-positive oral premalignant lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003; 95: 45-50. Ref.: https://goo.gl/kNxN1y

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?